Neuroprotexeon

NeuroproteXeon (NP) is a Buffalo, New York, NY based company developing the use of Xenon gas as a neuroprotective agent in patients suffering from neurologic injury. Xenon is delivered through an Inhalation device to patients following critical neurologic injury, reducing cell damage.
The use of xenon as a neuroprotective agent is aimed to improve mortality rates and neurologic function in patients experiencing acute injury to the brain.
Developed by company founders Mervyn Maze, MB, ChB and Nicholas Franks FRs, is currently preparing for a Phase III clinical trial in Out of Hospital Cardiac Arrest (OHCA) patients.
Xenon as anesthetic
Xenon has been used for over 60 years as an anesthetic. It has proven to have cardioprotective and neuroprotective properties. The use of xenon gas in conjunction with hypothermia has demonstrated positive neuroprotective properties.
Clinical trials
Positive preclinical work has led to Phase II trials designed to study the effects the use of xenon has on brain tissue. Results of Phase II trials are forthcoming.
NeuroproteXeon is initially pursuing two indications: cardiac arrest and anesthetic-induced developmental neurotoxicity (AIDN). Current preparations are for Phase III Clinical Trial in Out of Hospital Cardiac Arrest (OHCA) patients.
Founders
Mervin Maze, MD, Chief Medical Officer, co-inventor of the company’s xenon neuroprotective technology and of Precedex™ (dexmedetomidine), a sedative medication used by intensivist and anesthesiologists. Maze has served as Chair of Anesthesia and Critical Care at Imperial College, London and University of California San Francisco where he is an Endowed Tenured Professor of Anesthesia.
Nicholas Franks, FRS, Chairman, NeuroproteXeon Founder. Franks is a Biophysicist and Head of Biophysics at Imperial College, London. He is filer of patents of Xenon for neuroprotection.

Main Menu

See Also

Main Menu